Please see below to view details for this session presenter

Philip Jones, PhD

Head of Drug Discovery, Institute for Applied Cancer Science

Dr. Jones has more than a decade of drug discovery research experience from Merck Research Laboratories at three locations worldwide. During his career, Dr. Jones has led several of Merck’s oncology drug discovery programs, overseeing cross-functional project teams that have successfully delivered novel candidates into ongoing clinical trials. These include Merck’s PARP inhibitor, smoothened antagonist and histone deacetylase (HDAC) programs, as well as several undisclosed targets. Jones also was involved in the successful development of Raltegravir, the first-in-class HIV integrase inhibitor. He has extensive drug discovery experience across a broad range of target families and has coordinated research across the entire preclinical spectrum from target identification to lead optimization. Jones received his Ph.D. in organic chemistry from the University of Nottingham, United Kingdom, and completed his post-doctoral research in the laboratory of Professor P. Knochel at Philipps-Universität Marburg, Germany.